May 18, 2015
NuSirt Biopharma Raises $6 Million in Series C Funding
NASHVILLE, Tenn.–(BUSINESS WIRE)–NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, announced it has raised $6 million in Series C financing, of which $2 million has been funded. Hatteras Venture Partners was joined by existing stockholders, including Mountain Group Partners and TriStar Technology Ventures.
May 7, 2015
Spyryx Biosciences Secures $18 Million in Series A Financing
Research Triangle Park, NC, May 7, 2015 – Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD), announced today that it has secured $18 million in Series A venture capital financing from Canaan Partners, Hatteras Venture Partners and 5AM Ventures.
May 4, 2015
Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma
Alpharetta, GA and Emeryville, CA (May 4, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma.
April 29, 2015
Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye
PHILADELPHIA, Penn., April28, 2015 – Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. announced today that they have entered into an option agreement under which Spark acquired exclusive rights to license Clearside’s microinjector technology to deliver gene therapies to the back of the eye. Under the agreement, the companies will explore the feasibility of using Clearside’s microinjector technology to deliver viral vectors to the choroid and the retina through the suprachoroidal space (SCS).
April 20, 2015
Contego Medical Closes $5.6 Million in Series B Funding
RALEIGH, N.C., April 17, 2015 /PRNewswire/ — Contego Medical, the first and only provider of the Integrated Embolic Protection™ filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine. The round also included Mountain Group Partners, Lookout Capital and Medical Mutual.
March 17, 2015
GrayBug to Participate in 7th Ocular Diseases Drug Discovery Conference
BALTIMORE (March 17, 2015) – GrayBug Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced that its co-founder and Chief Scientific Officer Dr. Justin Hanes will deliver the keynote presentation, titled “The Dawn of Nanotechnology in Ocular Therapeutics” at the 7th Ocular Diseases Drug Discovery Conference at the Westin San Diego on Thursday, March 19 at 8:00 a.m.
March 12, 2015
PhaseBio Raises $40 Million Series C Financing Led By AstraZeneca
Malvern, PA, March 12, 2015 — PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that it has closed a $40 million Series C financing round led by AstraZeneca.
March 10, 2015
GrayBug Raises $1.74 Million in Series A2 Financing
BALTIMORE (March 10, 2015) – GrayBug, Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced the closing of a $1.74 million Series A2 financing round led by new investor Hatteras Venture Partners and existing investor Maryland Venture Fund.
February 13, 2015
ORIG3N™ Closes $3.1 Million in Funding Lead by Hatteras Venture Partners
BOSTON – February 5, 2015 – ORIG3N, Inc., a pioneer in regenerative medicine and provider ofpluripotent stem cell storage, has raised $3.1 million in funding from an investor syndicate that includes Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.
February 9, 2015
Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing
CAMBRIDGE, Mass. — Feb. 3, 2015 — Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $20 million in Series A financing.